We are live on
!
Find out more
KL
KCK Ltd Portfolio holdings
AUM
$15.1M
1-Year Est. Return
30.14%
This Fund
S&P 500
This Quarter
Est. Return
+73.03%
1 Year Est. Return
+30.14%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$66.7M
AUM Growth
+$15.2M
(+29%)
Cap. Flow
$0
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
3
New
–
Increased
–
Reduced
–
Closed
–
Top Buys
No buys this quarter
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sight Sciences
SGHT
$286M
| $58.3M | 87.37% |
4,776,232
| – | – |
|
2
Neuropace
NPCE
$439M
| $8.38M | 12.55% |
5,621,111
| – | – |
|
|
RNTX
3
Rein Therapeutics
RNTX
$63.1M
| $52.9K | 0.08% |
22,341
| – | – |
|
Similar funds
LM
AVM
RCMU
TPC
SI
TAC
DADR
PM
KCK Ltd's Q4 2022 Portfolio in Review
As of Q4 2022, KCK Ltd held 3 positions worth $66.7M, up 29% from $51.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Trading was light in Q4 2022: portfolio turnover was 0%. KCK Ltd opened no new positions and made no exits, leaving the 3-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- KCK Ltd's ten largest holdings make up 100% of its $66.7M portfolio in Q4 2022.
- KCK Ltd opened 0 new positions and closed 0 in Q4 2022.
- KCK Ltd's portfolio value rose 29% quarter-over-quarter to $66.7M.
Based on KCK Ltd's 13F filing for Q4 2022, filed 31 Jan 2023.